Search Results - "аутоиммунные процессы"

1

Academic Journal

Combination of diabetes mellitus and thyroid pathology (literature review)

Authors: Liashuk, P. M., Liashuk, R. P., Skhodnitskyi, I. V., Aniskevich, I. V., Glugovska, S. V.

Source: Буковинський медичний вісник; Том 23, № 4 (92) (2019); 191-195
Буковинский медицинский вестник; Том 23, № 4 (92) (2019); 191-195
Bukovinian Medical Herald; Том 23, № 4 (92) (2019); 191-195

Subject Terms: 2. Zero hunger, 03 medical and health sciences, цукровий діабет, метаболізм, автоімунні процеси, тиреоїдна патологія, огляд, 0302 clinical medicine, сахарный диабет, метаболизм, аутоиммунные процессы, тиреоидная патология, обзор, diabetes mellitus, metabolism, autoimmune processes, thyroid pathology, review, 3. Good health

File Description: application/pdf

Access URL: http://e-bmv.bsmu.edu.ua/article/download/2413-0737.XXIII.4.92.2019.110/196979
http://e-bmv.bsmu.edu.ua/article/download/2413-0737.XXIII.4.92.2019.110/196979
http://e-bmv.bsmu.edu.ua/article/view/2413-0737.XXIII.4.92.2019.110
http://e-bmv.bsmu.edu.ua/article/view/2413-0737.XXIII.4.92.2019.110

View record at OpenAIRE

2

Academic Journal

TARDY IDEAS ON THE USE OF BIOLOGICAL AGENTS IN RHEUMATIC DISEASES ; Несвоевременные мысли о применении генно-инженерных биологических препаратов при ревматических болезнях

Authors: Yu. V. Muravyev, L. A. Muravyeva, Ю. В. Муравьев, Л. А. Муравьева

Source: Rheumatology Science and Practice; Vol 54, No 3 (2016); 361-366 ; Научно-практическая ревматология; Vol 54, No 3 (2016); 361-366 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20163

Subject Terms: риск развития рака и инфекций, adverse events, induced autoimmune processes, risk for cancer and infections, неблагоприятные реакции, индуцированные аутоиммунные процессы

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2234/1449; Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum. 2005;34:7-11. doi:10.1016/j.semarthrit.2005.01.003; Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs. 2005;65:661-94. doi:10.2165/00003495-200565050-00006; Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;95:2275-85. doi:10.1001/jama.295.19.2275; Genovese MC, Bathon JM, Fleischmann RM, et al. Long-term safety, efficacy and radiographic outcomes with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol. 2005;32:1232-42.; Lebwohl M, Gottlieb A, Wallis W, Zitnik R. Safety and efficacy of over 7 years of etanercept therapy ina global population of patients with rheumatoid arthritis. J Am Acad Dermatol. 2005;52:195. doi:10.1016/j.jaad.2004.10.788; Haraoui B, Keystone E. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr Opin Rheumatol. 2006;18:96-100. doi:10.1097/01.bor.0000198007.73320.6e; Rubin RL. Drug-induced lupus. Toxicology. 2005;209:135-47. doi:10.1016/j.tox.2004.12.025; Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part 1. Arthritis Rheum. 2008;58:15-25. doi:10.1002/art.23177; Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part 2. Arthritis Rheum. 2008;58:26-35. doi:10.1002/art.23176; Ioannidis JP, Karassa FB, Druyts E, et al. Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales. Nat Rev Rheumatol. 2013;11:665-73. doi:10.1038/nrrheum.2013.134; Light DW. Pharmaceutical sales representatives and patient safety. J Gen Intern Med. 2013;28 (11):1394. doi:10.1007/s11606-013-2559-1; Mintzes B, Lexchin J, Wilkes MS, et al. Pharmaceutical sales representatives and patient safety. J Gen Intern Med. 2013;28(11):1395. doi:10.1007/s11606-013-2563-5; Mintzes B, Lexchin J, Sutherland J, et al. Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States. J Gen Intern Med. 2013;28(10):1368-75. doi:10.1007/s11606-013-2411-7; Khan NA, Lombeida JI, Singh M, et al. Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis. Arthritis Rheum. 2012;64:2059-67. doi:10.1002/art.34393; Schmucker C, Schell LK, Portalupi S, et al. Extent of non-publication in cohorts of studies approved by research ethics committees or included in trial registries. PLoS One. 2014;9(12):e114023. doi:10.1371/journal.pone.0114023; Gotzsche PC. Reference bias in reports of drug trials. Br Med J (Clin Res Ed). 1987;295(6599):654-6. doi:10.1136/bmj.295.6599.654; Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308:898-908. doi:10.1001/2012.jama.10857; Yadav S, Singh S, Harmsen WS, et al. Effect of medications on risk of cancer in patients with inflammatory bowel diseases: A population-based cohort study from Olmsted County, Minnesota. Mayo Clin Proc. 2015 Jun;90(6):738-46. doi:10.1016/j.mayocp.2015.03.024. Epub 2015 May 9.; Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum. 2011;63:1479-85. doi:10.1002/art.30310; Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;(2):CD008794. doi:10.1002/14651858.CD008794.pub2; Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86(4):242-51. doi:10.1097/MD.0b013e3181441a68; Ramos-Casals M, Brito-Zeron P, Soto MJ, et al. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008;22(5):847-61. doi:10.1016/j.berh.2008.09.008; Ramos-Casals M, Perez-Alvarez R, Diaz-Lagares C, et al. Autoimmune diseases induced by biological agents: a doubleedged sword? Autoimmun Rev. 2010;9:188-93. doi:10.1016/j.autrev.2009.10.003; Ramos-Casals M, Brito-Zeron P, Munoz S, Soto MJ. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore). 2008;87:345-64. doi:10.1097/MD.0b013e318190f170; Perez-Alvarez R, Perez-de-Lis M, Ramos-Casals M; BIOGEAS study group. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25(1):56-64. doi:10.1097/BOR.0b013e32835b1366; Mendonc JA, Marques-Neto JF, Samara AM, Appenzeller S. Increased levels of rheumatoid factors after TNF inhibitor in rheumatoid arthritis. Rheumatol Int. 2012;32:815-8. doi:10.1007/s00296-011-1812-3; Parekh K, Ching D, Rahman MU, Stamp LK. Onset of Wegener's granulomatosis during therapy with golimumab for rheumatoid arthritis: a rare adverse event? Rheumatology (Oxford). 2010;49:1785-7. doi:10.1093/rheumatology/keq101; Fonollosa A, Artaraz J, Les I, et al. Sarcoid intermediate uveitis following etanercept treatment: a case report and review of the literature. Ocul Immunol Inflamm. 2012;20:44-8. doi:10.3109/09273948.2011.623212; Bessissow T, Renard M, Hoffman I, et al. Review article: nonmalignant haematological complications of antitumour necrosis factor alpha therapy. Aliment Pharmacol Ther. 2012;36:312-23. doi:10.1111/j.1365-2036.2012.05189.x; Illei GG, Shirota Y , Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62:542-52. doi:10.1002/art.27221; Муравьев ЮВ, Гридина ГИ, Каратеев ДЕ. Тромбоэмболия – неожиданная неблагоприятная реакция, возникшая в период применения ингибитора фактора некроза опухоли α адалимумаба. Научно-практическая ревматология. 2013;51(3):354-6 [Muravyev YV, Gridina GI, Karateev DE. Thromboembolism is an unexpected poor response resulting from the use of the tumor necrosis factor α inhibitor adalimumab. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(3):354-6 (In Russ.)]. doi:10.14412/1995-4484-2013-1514; Malisiewicz B, Murer C, Pachlopnik Schmid J, et al. Eosinophilia during psoriasis treatment with TNF antagonists. Dermatology. 2011;223:311-5. doi:10.1159/000334805; Aouba A, de Bandt M, Aslangul E, et al. Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab. Rheumatology (Oxford). 2003;42:800-2. doi:10.1093/rheumatology/keg187; Oda Y, Urushidani Y, Ooi S, et al. Hemophagocytic lymphohistiocytosis in a rheumatoid arthritis patient treated with infliximab. Intern Med. 2012;51:655-7. doi:10.2169/internalmedicine.51.5687; Numakura T, Matsuura Y, Takiguchi H, et al. Tuberculosis associated with hemophagocytic syndrome complicated by treatment with infliximab. Nihon Kokyuki Gakkai Zasshi. 2010;48:449-53.; Araki D, Fujii H, Matsumura M, et al. Etanercept-induced lupus accompanied by hemophagocytic syndrome. Intern Med. 2011;50:1843-8. doi:10.2169/internalmedicine.50.5430; Sandhu C, Chesney A, Piliotis E, et al. Macrophage activation syndrome after etanercept treatment. J Rheumatol. 2007;34:241-2.; Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2003;30:401-3.; Mehta BM, Hashkes PJ, Avery R, Deal CL. A 21-year-old man with Still's disease with fever, rash, and pancytopenia. Arthritis Care Res (Hoboken). 2010;62:575-9. doi:10.1002/acr.20001; Bosch X, Saiz A, Ramos-Casals M; BIOGEAS Study Group. Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol. 2011;7:165-72. doi:10.1038/nrneurol.2011.1; Nozaki K, Silver RM, Stickler DE, et al. Neurological deficits during treatment with tumor necrosis factor-alpha antagonists. Am J Med Sci. 2011;342:352-5. doi:10.1097/MAJ.0b013e31822b7bb8; Brigo F, Bongiovanni LG, Cerini R, et al. Infliximab-related seizures: a first case study. Epileptic Disord. 2011;13:214-7.; Stubgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve. 2008;37:281-92. doi:10.1002/mus.20924; Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, et al. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med. 2011;124:386-94. doi:10.1016/j.amjmed.2010.11.028; Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011;41:256-64. doi:10.1016/j.semarthrit.2010.11.002; Hadjinicolaou AV, Nisar MK, Parfrey H, et al. Noninfectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford). 2012;51:653-62. doi:10.1093/rheumatology/ker290; Wendling D, Paccou J, Berthelot JM, et al. New onset of uveitis during antitumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011;41:503-10. doi:10.1016/j.semarthrit.2011.05.005; Wendling D, Dernis E, Prati C, et al. Onset of inflammatory eye disease undertocilizumab treatment for rheumatologic conditions: a paradoxical effect? J Rheumatol. 2011;38:2284. doi:10.3899/jrheum.110170; Van Dijken TD, Vastert SJ, Gerloni VM, et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2011;38:1441-6. doi:10.3899/jrheum.100809; Toussirot E, Houvenagel E, Goö b V, et al. Development of inflammatory bowel disease during anti-TNF-a therapy for inflammatory rheumatic disease: a nationwide series. Joint Bone Spine. 2011 [Epub ahead of print].; Sekkach Y, Hammi S, Elqatni M, et al. Ulcerative colitis: exceptional consequence after rituximab therapy. Ann Pharm Fr. 2011;69:265-9. doi:10.1016/j.pharma.2011.06.005; Bhalme M, Hayes S, Norton A, et al. Rituximab-associated colitis. Inflamm Bowel Dis. 2012 [Epub ahead of print].; ElFassi D, Nielsen CH, Junker P, et al. Systemic adverse events following rituximab therapy in patients with Graves' disease. J Endocrinol Invest. 2011;34:e163-7.; Goetz M, Atreya R, Ghalibafian M, et al. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis. 2007;13:1365-8. doi:10.1002/ibd.20215; Ardelean DS, Gonska T, Wires S, et al. Severe ulcerative colitis after rituximab therapy. Pediatrics. 2010;126:e243-6. doi:10.1542/peds.2009-3395; Fiehn C, Vay S. Induction of inflammatory bowel disease flares by golimumab: report of three patients with enteropathic spondylarthritis or ankylosing spondylitis and comorbid colitis. Arthritis Rheum. 2011;63:3640-1. doi:10.1002/art.30546; Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40:233-40. doi:10.1016/j.semarthrit.2010.04.003; Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantarpustulosis associated with tumor necrosis factor-a inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol. 2011;67:e179-85. doi:10.1016/j.jaad.2011.05.038; Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving antitumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68:209-15. doi:10.1136/ard.2007.087288; Thomas L, Canoui-Poitrine F, Gottenberg JE, et al. Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: data from the French AIR registry. J Rheumatol. 2012;39:893-8. doi:10.3899/jrheum.111347; Kato K, Satoh T, Nishizawa A, Yokozeki H. Psoriasiform drug eruption due to abatacept. Acta Derm Venereol. 2011;91:362-3. doi:10.2340/00015555-1042; Konsta M, Rallis E, Karameris A, et al. Psoriasiform lesions appearing in three patients with rheumatoid arthritis during therapeutic administration of abatacept, a selective inhibitor of T-cell costimulation. J Eur Acad Dermatol Venereol. 2012;26:257-8. doi:10.1111/j.1468-3083.2011.04042.x; Brigant F, Clavel G, Chatelain D, et al. A case of generalized guttate psoriasis induced by etanercept with relapse after abatacept. Dermatol Online J. 2011;17:11.; Gonzalez-Lopez MA, Martinez-Taboada VM, Gonzalez-Vela MC, et al. Newonset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2008;158:1146-8. doi:10.1111/j.1365-2133.2008.08470.x; Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol. 2012;39:481-92. doi:10.1111/j.1600-0560.2012.01894.x; Brunasso AM, Laimer M, Massone C. Paradoxical reactions to targeted biological treatments: a way to treat and trigger? Acta Derm Venereol. 2010;90:183-5. doi:10.2340/00015555-0777; Piga M, Chessa E, Ibba V, et al. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort. Autoimmun Rev. 2014;13(8):873-9. doi:10.1016/j.autrev.2014.05.005

Availability: https://rsp.mediar-press.net/rsp/article/view/2234
https://doi.org/10.14412/1995-4484-2016-361-366

View record from BASE

3

Academic Journal